-
1 month ago | 
ankylosingspondylitisnews.com | Lindsey Shapiro |Steve Bryson |Alexandra Fendrich |Andrea Lobo
A version of Purified Cortrophin Gel (repository corticotropin injection) that comes in a prefilled syringe has been approved by the U.S. Food and Drug Administration (FDA) for treating ankylosing spondylitis (AS) and other inflammatory diseases. The injectable treatment from Ani Pharmaceuticals initially was approved in 2021 for a range of conditions, including as a short-term, add-on therapy to help manage acute exacerbations in rheumatic conditions like AS.
-
2 months ago | 
ankylosingspondylitisnews.com | Alexandra Fendrich |Lisa Marie Basile |Jemma Newman |Margarida Maia
One evening in December, I scrolled through photos on my phone, looking back at each moment in time.
-
Nov 12, 2024 | 
ankylosingspondylitisnews.com | Alexandra Fendrich |Andrea Lobo |Marta C. Figueiredo |Iqra Mumal
It’s been a while since my last column, and I apologize for that. I’ll try to unpack several of the challenges that have come up for me in recent months. While they’re not all directly linked to ankylosing spondylitis (AS), I believe that many of you will relate to some of the lessons I’ve learned. In mid-September, I was dealing with a persistent symptoms flare, so I made an appointment to see my rheumatologist.
-
Sep 16, 2024 | 
ankylosingspondylitisnews.com | Esteban Cerezo |Alexandra Fendrich |Jemma Newman |Patricia Inacio
Lower socioeconomic status is associated with more severe disease, longer diagnosis delays, and permanent disability in people with ankylosing spondylitis (AS), a Spanish study showed. Even with similar access to disease-modifying anti-rheumatic drugs (DMARDs), socioeconomic status may be a significant factor for understanding health outcomes differences between AS patients, the scientists suggested.
-
Aug 13, 2024 | 
ankylosingspondylitisnews.com | Alexandra Fendrich |Margarida Maia |Andrea Wyckoff |Lisa Marie Basile
In November 2022, after a tearful Minion-themed goodbye party, I did what I thought was the best model for my seventh graders: I told them I needed to put my health first. I resigned from my position as a full-time special education teacher in a middle school and switched to a hybrid role working as a program manager at an education nonprofit.
-
Aug 12, 2024 | 
ankylosingspondylitisnews.com | Steve Bryson |Alexandra Fendrich |Margarida Maia |Patricia Inacio
Genetic analyses found altered activity in several genes related to programmed cell death in ankylosing spondylitis (AS) patients that was not evident in healthy individuals, a study reported. Significantly distinct genetic differences between men and women with AS also were identified, which researchers suggest may serve as new sex-specific disease biomarkers.
-
Jul 29, 2024 | 
ankylosingspondylitisnews.com | Margarida Maia |Alexandra Fendrich |Marisa Wexler MS
Rinvoq (upadacitinib) appears to be the most effective treatment to reduce disease activity in people with ankylosing spondylitis (AS), whether they had never been on tumor necrosis factor inhibitors (TNFi) or didn’t respond well to them, a study suggests. Because the observations come from indirect comparisons of data from randomized controlled trials, “head-to-head and real-world data comparisons are warranted to both validate these findings and aid medical decision makers,” researchers wrote.
-
Jul 9, 2024 | 
ankylosingspondylitisnews.com | Alexandra Fendrich |Margarida Maia |Jemma Newman
It’s summer, which means I want to spend more time outside, preferably near water with an ice cream in hand. Living with ankylosing spondylitis (AS) has required me to have a different form of “hot girl summer,” though, as I manage the ups and downs of flares — periods of disease when my pain and stiffness increase. Beyond trying various medications, I’ve identified strategies to help me function amid periods of high inflammation. They’ve been crucial to how I navigate my disease.
-
Jul 8, 2024 | 
ankylosingspondylitisnews.com | Marisa Wexler MS |Alexandra Fendrich |Steve Bryson
One year of treatment with Rinvoq (upadacitinib) reduced disease activity for most adults with non-radiographic axial spondyloarthritis (nr-axSpA) — an inflammatory condition related to ankylosing spondylitis (AS) — in a Phase 3 clinical trial. “These longer-term results continue to support the favorable benefit-risk profile of [Rinvoq] once daily in patients with active nr-axSpA,” the researchers wrote.
-
Jun 25, 2024 | 
ankylosingspondylitisnews.com | Alexandra Fendrich |Marisa Wexler MS |Steve Bryson |Andrea Lobo
Note: This column describes the author’s own experiences with an il-17 inhibitor. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. When my rheumatologist first told me we were going to try a biologic medication to treat my ankylosing spondylitis (AS), I felt mixed emotions. On one hand, I was nervous, especially because I had to inject the medicine myself.
